Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 11, 2019. The document serves as a transaction notification regarding dealings by a Person Discharging Managerial Responsibilities (PDMR) rather than a financial results report.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It contains only specific transaction data related to share options:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Exercise of options followed by a sale.
- Volume: 6,910 shares.
- Exercise Price: £11.7700 per share.
- Sale Price: Not disclosed in the filing text.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses a change in the shareholding of a specific executive.
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a regulatory disclosure of a transaction executed by Mr. R G Connor, President of Global Vaccines.
- Transaction Date (Exercise): February 8, 2018.
- Transaction Date (Sale): February 8, 2019.
- Exchange: London Stock Exchange (XLON).
Investor Verification Points
- Verify the actual sale price of the 6,910 shares, as the filing lists the exercise price (£11.77) but omits the sale price.
- Confirm the total shareholding of Mr. R G Connor post-transaction to assess insider sentiment.
- Note that this filing does not reflect the company's quarterly or annual financial performance.